IonQ (IONQ) recently experienced a significant price move of approximately 51% over the last quarter, potentially influenced by key executive appointments and strategic alliances. The addition of Dr.

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

The FTSE 100 concluded the day with a 0.6% increase, driven by healthcare gains and AstraZeneca's strong profit report.

The biggest fallers on the FTSE 100 were Croda International, down 301p at 2,598p; Rentokil Initial, down 12.9p at 348.1p; ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0452 ET – Philips’s strong quarterly results and guidance raise ...

A formal trade agreement between the US and EU introduces a 15% tariff on most EU exports, including pharmaceuticals, ...

Imfinzi plus chemo cut progression or death risk in early gastric cancer; the FDA's decision is expected late 2025 following breakthrough designation.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...